On a molecular level, O-6-methylguanine-DNA methyltransferase (MGMT) hypermethylation (increased efficacy of alkylating agents [13]) and IDH1/2 mutation (secondary GBM [8,14,15]) are the most important prognostic markers used in clinical routine [16,17,18]. Here, IDH1 is linked to glioblastoma.